Skip to Content

Chinook Therapeutics, Inc.

Company NameChinook Therapeutics, Inc.
Stock SymbolKDNY

On May 16, 2023, Muddy Waters Research published a report alleging that Chinook’s lead product candidate, atrasentan, “has been shown to be harmful to patients’ cardiovascular health,” and that “AbbVie and Chinook seem to have systemically manipulated research findings and presentation on atrasentan to obscure these trial results.”

On this news, Chinook’s stock price fell $1.64 per share, or 7%, to close at $21.76 per share on March 16, 2023, thereby injuring investors. 

Submit Your Information

If you suffered a loss on your Chinook Therapeutics, Inc. investments or would like to inquire about joining an action to recover your loss under the federal securities laws, please complete the form below. Please note that submission of this form does not by itself form an attorney-client relationship nor does filing out this form mean you have joined any lawsuit.

Shares Purchased

Number of SharesBuy DatePrice Per ShareAdd

Shares Sold

Number of SharesSell DatePrice Per ShareAdd